GLEEVEC® is indicated for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase.
GLEEVEC® is also indicated for the treatment of adult patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase (after failure of interferon-alpha therapy).
GLEEVEC® is also indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
GLEEVEC® is also indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
GLEEVEC® is also indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as single agent.
GLEEVEC® is also indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
GLEEVEC® is also indicated for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SM-AHNMD1) without the D816V c-Kit mutation. If c-Kit mutational status in patients with ASM or SM-AHNMD1 is not known or unavailable, treatment with GLEEVEC® may be considered if there is no satisfactory response to other therapies.
GLEEVEC® is also indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.
GLEEVEC® is also indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
GLEEVEC® is also indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
GLEEVEC® is also indicated for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.
